Vaccines Market by Type, Technology Type, Route of administration, Indication, Age Group

List of Tables

The Vaccines Market was valued at USD 68.92 billion in 2023, expected to reach USD 74.16 billion in 2024, and is projected to grow at a CAGR of 7.70%, to USD 115.89 billion by 2030.

Vaccines are biological preparations that provide immunity against specific diseases and are critical in preventive healthcare. The vaccine market encompasses a broad spectrum including prophylactic vaccines for disease prevention and therapeutic vaccines for disease treatment. The necessity of vaccines has been underscored by global health challenges such as the COVID-19 pandemic, increasing the demand for novel vaccine technologies like mRNA vaccines. Applications extend beyond infectious diseases to areas such as cancer, allergies, and autoimmune disorders, while end-use sectors include hospitals, clinics, and research institutes. A significant growth factor is the increased awareness and investments in immunization programs worldwide, further propelled by government and non-governmental organizations. Technological advancements, coupled with expanding research and development funding, present lucrative opportunities for stakeholders to innovate in vaccine delivery mechanisms and stability. However, challenges such as stringent regulatory policies, high R&D costs, and vaccine hesitancy might impede market growth. Moreover, supply chain disruptions and inequitable access in developing countries represent substantial limitations. Promising areas for innovation and research include personalized vaccines, adjuvant technology, and needle-free delivery systems, which could enhance effectiveness and patient compliance. Insights indicate that collaboration between pharmaceutical companies, tech firms, and public health organizations can accelerate breakthroughs. Exploring digital health solutions for enhancing vaccine distribution efficiency and outcome tracking presents untapped potential. Despite the competitive landscape, the market's inherent expansion is nurtured by evolving therapeutic needs and the imperative for global public health security. Overall, the vaccine market holds promise for continuous growth, contingent upon addressing challenges of accessibility and affordability, while leveraging technological innovations to tap into emerging opportunities like personalized immunotherapy and blockchain for supply chain transparency.

KEY MARKET STATISTICS
Base Year [2023]	USD 68.92 billion
Estimated Year [2024]	USD 74.16 billion
Forecast Year [2030]	USD 115.89 billion
CAGR (%)	7.70%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vaccines Market

The Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Prevalence of new infectious diseases and increase in awareness about the benefits of vaccination
- Increased government funding encouraging vaccine development
Market Restraints
- High development costs and Issues over product recalls
Market Opportunities
- Surge in investments by biotech companies for innovative vaccine development
- Emerging collaborations between public and private sectors improve vaccine distribution
Market Challenges
- Lengthy vaccine approval processes and associated side impacts of vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vaccines Market

A detailed market share analysis in the Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vaccines Market

A strategic analysis of the Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Biological E. Limited, BioNTech SE, Blue Lake Biotechnology, Capricor Therapeutics, Inc., Chongqing Zhifei Biological Products Co., Ltd., CSL Limited, CureVac N.V., Daiichi Sankyo Company, Limited., Emergent BioSolutions Inc., Gennova Biopharmaceuticals Limited, GlaxoSmithKline PLC, Haffkine Bio-Pharmaceutical Corporation Ltd, Incepta Pharmaceuticals Ltd., Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna, Inc., Novavax, Inc., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, VBI Vaccines Inc., Versatope Therapeutics, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Type, market is studied across Monovalent Vaccine and Multivalent Vaccine.
Based on Technology Type, market is studied across Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA (mRNA) Vaccines, Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines, Toxoid Vaccines, and Viral Vector Vaccines.
Based on Route of administration, market is studied across Intramuscular & Subcutaneous and Oral.
Based on Indication, market is studied across Haemophilus Influenzae Type b, Hepatitis A & Hepatitis B, Human Papillomavirus, Measles, Mumps, & Rubella, Meningococcal Disease, Pneumococcal Disease, Polio, Rabies, Rotavirus, Shingles/Herpes Zoster, Tetanus, Diphtheria, & Pertussis, and Varicella.
Based on Age Group, market is studied across Adults and Pediatric.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-434CCDA0513E

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of new infectious diseases and increase in awareness about the benefits of vaccination
  - 5.1.1.2. Increased government funding encouraging vaccine development
- 5.1.2. Restraints
  - 5.1.2.1. High development costs and Issues over product recalls
- 5.1.3. Opportunities
  - 5.1.3.1. Surge in investments by biotech companies for innovative vaccine development
  - 5.1.3.2. Emerging collaborations between public and private sectors improve vaccine distribution
- 5.1.4. Challenges
  - 5.1.4.1. Lengthy vaccine approval processes and associated side impacts of vaccines
5.2. Market Segmentation Analysis
- 5.2.1. Type: Critical need for Multivalent vaccines in case of exposure to various strains
- 5.2.2. Technology Type: Growing significance of mRNA vaccines due to their rapid development and high efficacy
- 5.2.3. Route of Administration: High preferences for intramuscular (IM) and subcutaneous (SC) routes owing to their strong immune response
- 5.2.4. Indication: Widespread adoption of influenza vaccines for preventing seasonal flu outbreaks
- 5.2.5. Age Group: Need for effective vaccination for the elderly and individuals with chronic health conditions
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Vaccines Market, by Type

6.1. Introduction
6.2. Monovalent Vaccine
6.3. Multivalent Vaccine

7. Vaccines Market, by Technology Type

7.1. Introduction
7.2. Inactivated Vaccines
7.3. Live-Attenuated Vaccines
7.4. Messenger RNA (mRNA) Vaccines
7.5. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
7.6. Toxoid Vaccines
7.7. Viral Vector Vaccines

8. Vaccines Market, by Route of administration

8.1. Introduction
8.2. Intramuscular & Subcutaneous
8.3. Oral

9. Vaccines Market, by Indication

9.1. Introduction
9.2. Haemophilus Influenzae Type b
9.3. Hepatitis A & Hepatitis B
9.4. Human Papillomavirus
9.5. Measles, Mumps, & Rubella
9.6. Meningococcal Disease
9.7. Pneumococcal Disease
9.8. Polio
9.9. Rabies
9.10. Rotavirus
9.11. Shingles/Herpes Zoster
9.12. Tetanus, Diphtheria, & Pertussis
9.13. Varicella

10. Vaccines Market, by Age Group

10.1. Introduction
10.2. Adults
10.3. Pediatric

11. Americas Vaccines Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Vaccines Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Vaccines Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. Mankind Pharma to Acquire Bharat Serums and Vaccines in USD 2 Billion Deal, Expanding Vaccine Production Capabilities
- 14.3.2. Sanofi and Novavax Partner to Co-Commercialize New COVID-19 Vaccine and Develop Flu-COVID Combo Shot
- 14.3.3. CureVac and MD Anderson Team Up to Develop mRNA-Based Cancer Vaccines, Paving the Way for Advanced Cancer Treatments
- 14.3.4. Bharat Biotech and Bilthoven Biologicals Unite to Boost Global Polio Eradication Efforts with Enhanced OPV Production
- 14.3.5. Takeda Forms Partnership to Boost Global Access to Dengue Vaccine, Targeting Hard-Hit Regions
- 14.3.6. AstraZeneca Bolsters Vaccine Capabilities by Acquiring Biotechnology Firm Icosavax
- 14.3.7. Serum Institute of India Partners with CEPI to Boost Global Vaccine Accessibility During Epidemics
- 14.3.8. GSK Partners with Zhifei to Exclusively Distribute Shingles Vaccine Shingrix in China, Aiming to Enhance Public Health and Vaccine Access
- 14.3.9. Janssen and Sanofi Join Forces to Develop Vaccine Program to Address Unmet Medical Needs
- 14.3.10. Global Initiative Boosts Pandemic Preparedness with Funding for Gennova's Self-Amplifying mRNA Vaccine against Disease X
- 14.3.11. Bavarian Nordic Launches Mpox Vaccine in the U.S., Boosting Preventive Healthcare and Market Innovation
14.4. Strategy Analysis & Recommendation
- 14.4.1. AstraZeneca PLC
- 14.4.2. Pfizer Inc.
- 14.4.3. GlaxoSmithKline PLC
- 14.4.4. Merck & Co., Inc.
- 14.4.5. Sanofi S.A.

Companies Mentioned

1. Abbott Laboratories
2. Astellas Pharma Inc.
3. AstraZeneca PLC
4. Bavarian Nordic A/S
5. Bharat Biotech Ltd.
6. Biological E. Limited
7. BioNTech SE
8. Blue Lake Biotechnology
9. Capricor Therapeutics, Inc.
10. Chongqing Zhifei Biological Products Co., Ltd.
11. CSL Limited
12. CureVac N.V.
13. Daiichi Sankyo Company, Limited.
14. Emergent BioSolutions Inc.
15. Gennova Biopharmaceuticals Limited
16. GlaxoSmithKline PLC
17. Haffkine Bio-Pharmaceutical Corporation Ltd
18. Incepta Pharmaceuticals Ltd.
19. Inovio Pharmaceuticals, Inc.
20. Johnson & Johnson Services, Inc.
21. Merck & Co., Inc.
22. Moderna, Inc.
23. Novavax, Inc.
24. Pfizer Inc.
25. Sanofi S.A.
26. Serum Institute of India Pvt. Ltd.
27. Sinovac Biotech Ltd.
28. Takeda Pharmaceutical Company Limited
29. VBI Vaccines Inc.
30. Versatope Therapeutics
31. Zydus Lifesciences Limited